Goodwin Procter advised TPI Composites, Inc. on the deal. Davis Polk advised the representative of the initial purchasers and the counterparties to the capped call transactions...
You must be a Standard 1 Year member to access this content.
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Bicara Therapeutics on the deal. Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised SonoThera, Inc. on the deal. SonoThera, Inc. announced its $60.75 million Series A financing round to support the continued development of SonoThera’s ultrasound-guided, nonviral,...
You must be a Standard 1 Year member to access this content.
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Entrada Therapeutics, Inc. on the deal. Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its global collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to focus...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised FibroGen, Inc. on the deal. FibroGen, Inc. announced its capped royalty monetization financing with NovaQuest Capital Management. The non-dilutive financing provides FibroGen with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced its Research Collaboration and License Agreement with Eli Lilly and Company for the exclusive and worldwide...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the initial purchasers on the deal. Sarepta Therapeutics, Inc. announced its Rule 144A offering of 1.25% Convertible Senior Notes due 2027. The $1.15 billion...
You must be a Standard 1 Year member to access this content.
Goodwin Procter represented Wayfair, while Davis Polk advised the representatives of the initial purchasers in the offering. Wayfair Inc. completed its offering of $690 million aggregate principal...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Alnylam Pharmaceuticals, Inc. on the deal, while Davis Polk advised the representative of the initial purchasers. Alnylam Pharmaceuticals, Inc. announced its inaugural offering...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Ampersand Capital Partners on the deal. Ampersand Capital Partners announced its first and only closing of Ampersand 2022 Limited Partnership with $1.2 billion in...
You must be a Standard 1 Year member to access this content.
